The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
The in-vitro activities of four anticancer alkyllysophospholipids, ET-18-OCH3 (edelfosine), hexadecylphosphocholine (miltefosine), ilmofosine and SRI 62-834, were determined with ED50 values for Leishmania donovani and Trypanosoma cruzi amastigotes between 0.2 and 5.0 microM and for Trypanosoma brucei trypomastigotes between 7.0 and 50.8 microM. In BALB/c mice miltefosine and ilmofosine were the most active compounds with ED50 values of 2.9 and 14.5 mg/kg x 5 doses against L. donovani and a suppressive effect on T. cruzi infections at 30 mg/kg x 5 doses.
Croft
S L
SL
Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, UK.
Snowdon
D
D
Yardley
V
V
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014355:Chagas Disease / Q000188:drug therapy*; D006224:Cricetinae; D005260:Female; D005663:Furans / Q000494:pharmacology; D007893:Leishmania donovani / Q000187:drug effects; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008246:Lysophospholipids / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D010742:Phospholipid Ethers / Q000494:pharmacology; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014344:Trypanocidal Agents / Q000494:pharmacology*; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014349:Trypanosoma cruzi / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D000970:Antineoplastic Agents; D005663:Furans; D008246:Lysophospholipids; D010742:Phospholipid Ethers; D014344:Trypanocidal Agents; D010767:Phosphorylcholine; C055462:SRI 62-834; C026659:edelfosine; C039128:miltefosine; C043297:ilmofosine